Oramed Pharmaceuticals (NASDAQ:ORMP) received a $20.00 price target from stock analysts at HC Wainwright in a research note issued to investors on Wednesday, TipRanks reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock.
Several other analysts also recently weighed in on the stock. ValuEngine raised shares of Oramed Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. LADENBURG THALM/SH SH assumed coverage on shares of Oramed Pharmaceuticals in a report on Wednesday, September 11th. They issued a “buy” rating and a $7.00 target price on the stock.
Shares of NASDAQ:ORMP traded down $0.06 during midday trading on Wednesday, hitting $3.10. The stock had a trading volume of 64,469 shares, compared to its average volume of 54,104. The company has a market capitalization of $55.62 million, a PE ratio of -3.60 and a beta of 1.27. The stock has a 50 day moving average price of $3.26 and a two-hundred day moving average price of $3.43. Oramed Pharmaceuticals has a 1 year low of $2.78 and a 1 year high of $4.99.
Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its earnings results on Wednesday, July 10th. The biotechnology company reported ($0.23) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.23). The business had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.71 million. Oramed Pharmaceuticals had a negative net margin of 568.43% and a negative return on equity of 56.15%. Equities analysts forecast that Oramed Pharmaceuticals will post -0.96 earnings per share for the current fiscal year.
In related news, Director Leonard Sank acquired 20,000 shares of Oramed Pharmaceuticals stock in a transaction that occurred on Tuesday, July 16th. The stock was purchased at an average price of $3.47 per share, for a total transaction of $69,400.00. Following the completion of the purchase, the director now directly owns 315,482 shares of the company’s stock, valued at $1,094,722.54. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders purchased 50,817 shares of company stock valued at $164,009 in the last quarter. Company insiders own 20.50% of the company’s stock.
A hedge fund recently bought a new stake in Oramed Pharmaceuticals stock. Jane Street Group LLC acquired a new stake in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 43,212 shares of the biotechnology company’s stock, valued at approximately $155,000. Jane Street Group LLC owned 0.25% of Oramed Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 4.83% of the company’s stock.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.
Featured Article: What is a management fee?
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.